VetMedChronic enteropathy in dogs: does a multi-strain probiotic vs placebo improve clinical scores and reduce relapse? — POSSIBLE (the treatment made no difference to clinical remission)
In dogs with chronic enteropathy, does a multi-strain probiotic vs placebo improve clinical scores and reduce relapse?
Shelf #394 · gate-verified and displayed under the developer's blinded-trial rule
POSSIBLE (the treatment made no difference to clinical remission): In the one randomised, blinded, placebo-controlled trial of a multi-strain probiotic in canine chronic enteropathy, adding the probiotic to standard therapy changed nothing clinical. In White 2017 (PMID: 28678609; 34 dogs with idiopathic inflammatory bowel disease randomised at three US centres, 26 completing; full text, PMC), standard therapy (elimination diet plus prednisone) plus an 8-strain probiotic (the De Simone formulation) was compared with the same standard therapy plus an identical maltodextrin placebo capsule, with the veterinary gastroenterologist and the client blinded: clinical remission at visit 2 was 12/14 (86%) with probiotic vs 10/12 (83%) with placebo, at 8 weeks only 1 dog in each group had failed to achieve full clinical remission (13/14 vs 11/12), canine inflammatory bowel disease activity index (CIBDAI) scores fell significantly in both groups (P < 0.001 vs baseline), and histopathologic inflammation improved in neither group. The probiotic's measurable effects were microbial and molecular only (increased mucosal Lactobacillus spp; upregulated tight-junction protein expression). The relapse half of this shelf's question is UNTESTED by that trial: the final visit was at 8 weeks, on treatment, with no post-treatment follow-up. The supporting placebo records point the same way: a probiotic cocktail trial in food-responsive diarrhoea (Sauter 2006, PMID: 16867072) saw the clinical activity index fall in all dogs regardless of allocation, and a blinded pilot of a single-strain Enterococcus faecium synbiotic vs placebo (Schmitz 2015, PMID: 25776251) found no difference in clinical efficacy. Narrowing stated on the face: the carded placebo evidence is for probiotic ADDED TO standard therapy (diet, and in White 2017 prednisone) in inflammatory bowel disease / food-responsive enteropathy — no fetched record tests a probiotic alone against placebo alone, and none measures relapse after stopping. Design class (a): White 2017 establishes randomisation (computer-generated schedule, full text) AND blinding (identical placebo capsules; gastroenterologist and client blinded, full text) AND answers this shelf's own comparison (multi-strain probiotic vs placebo, as an add-on to standard therapy) in this shelf's population (dogs with chronic enteropathy/IBD). Tier C is not engaged: no mortality or survival claim is made anywhere on this shelf. Drafted Nov 10, 2026 (VetMed build, topic #394); figures from the abstract and the PMC full text, fetched and verified at drafting.
White 2017: multi-strain probiotic added to standard therapy gave clinical remission in 12/14 (86%) vs 10/12 (83%) on placebo at visit 2, and 13/14 vs 11/12 at 8 weeks — no clinical difference in a randomised, blinded, placebo-controlled trial
Randomized, controlled trial (record's own title wording) — full text establishes computer-generated randomisation, identical maltodextrin placebo capsules, and blinding of the veterinary gastroenterologist and client; the abstract alone does not state the placebo or blinding, and the full text governs
Who: Dogs: 34 client-owned dogs with idiopathic inflammatory bowel disease (persistent or intermittent gastrointestinal signs for at least 3 weeks, other causes excluded, failed prior diet and metronidazole trials, histopathologic mucosal inflammation) randomised at three US centres (Iowa State, Colorado State, Veterinary Specialty Hospital San Diego) to standard therapy (ST: elimination diet plus oral prednisone, tapered over 8 weeks) with either a multi-strain probiotic or placebo; 26 dogs completed (14 probiotic, 12 ST/placebo). Per the full text (PMC), randomisation was by computer-generated schedule; the probiotic was the 8-strain De Simone formulation (Lactobacillus plantarum, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus paracasei, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium infantis; 112–225 × 10^9 CFU/10 kg) and dogs randomised to ST received an identical capsule containing maltodextrin as placebo; both the veterinary gastroenterologist and the client were blinded. Mean baseline CIBDAI was 6.7 (probiotic) vs 8.1 (ST). Eight dogs with low cobalamin were also treated for cobalamin deficiency.
Result: Both treatments were associated with significantly reduced CIBDAI scores at visits 2 (~3 weeks) and 3 (8 weeks) compared with visit 1 (P < 0.001). Clinical remission (defined in the full text as a decrease in CIBDAI of 50% or more at visit 2, and 75% or more at visit 3) was observed at visit 2 in 12/14 (86%) of dogs receiving ST/probiotic and 10/12 (83%) of dogs receiving ST (placebo); at visit 3, only 1 dog in each treatment group had failed to achieve full clinical remission (13/14 vs 11/12). Total histopathologic scores did not improve with either treatment (ST P = 0.18; ST/probiotic P = 0.08). Probiotic therapy was associated with increased mucosal Lactobacillus spp and upregulated (P < 0.05) expression of the tight-junction proteins E-cadherin, occludin and zonulin vs ST — laboratory effects without a clinical-score advantage.
Watch out: This is an ADD-ON comparison: every dog received an elimination diet and prednisone, which themselves produced rapid remission in both arms, so the trial tests whether probiotic adds anything to standard therapy — not probiotic vs placebo as sole treatment. Twenty-six of 34 randomised dogs completed, below the trial's own 16-per-group power target, and the authors state the trial lacked sufficient power to definitively define a between-group effect — a small added benefit is not excluded. The population is idiopathic IBD specifically (dogs that had already failed diet and metronidazole), and there was no follow-up after treatment stopped, so this record says nothing about relapse. The tested product is one specific 8-strain formulation; the result does not automatically transfer to other probiotic products.
White R, Atherly T, Guard B, Rossi G, Wang C, Mosher C, Webb C, Hill S, Ackermann M, Sciabarra P, Allenspach K, Suchodolski J, Jergens AE. Randomized, controlled trial evaluating the effect of multi-strain probiotic on the mucosal microbiota in canine idiopathic inflammatory bowel disease. Gut Microbes. 2017;8(5):451-466. PMID: 28678609. Registry ID: none in the record. MeSH: Animals · Dog Diseases/pathology*, therapy* · Dogs · Gastrointestinal Microbiome* · Gastrointestinal Tract/pathology · Histocytochemistry · Inflammatory Bowel Diseases/pathology, therapy, veterinary* · Probiotics/administration & dosage* · Treatment Outcome
Sauter 2006: in food-responsive diarrhoea, the clinical activity index fell in ALL dogs (P < 0.0001) whether they received the probiotic cocktail or placebo
Prospective placebo-controlled probiotic trial (record's abstract wording; MeSH carries Double-Blind Method; the abstract does not state randomisation)
Who: Dogs: 21 client-owned dogs with food-responsive diarrhoea presented for clinically needed duodenoscopy and colonoscopy, enrolled in a prospective placebo-controlled probiotic trial (record's MeSH includes Double-Blind Method). Dogs received an elimination diet with either a probiotic cocktail (a lyophilised cocktail of Lactobacillus spp strains, per the trial's description in the later literature) or placebo; intestinal biopsies and faeces were collected at endoscopy before and during treatment, and the canine inflammatory bowel disease activity index (CIBDAI) was scored.
Result: The CIBDAI — comprising general attitude, appetite, faecal consistency, defecation frequency and vomitus — decreased in all dogs (P < 0.0001), with no probiotic-specific clinical advantage reported in the record's abstract. Duodenal interleukin-10 mRNA levels decreased (P = 0.1) and colonic interferon-gamma mRNA levels increased (P = 0.08) after probiotic treatment, and Enterobacteriaceae numbers decreased in both the probiotic and placebo groups (P < 0.05); the authors concluded that all dogs clinically improved after treatment but cytokine patterns were not associated with the clinical features, irrespective of dietary supplementation.
Watch out: The population is food-responsive diarrhoea — the enteropathy subtype expected to respond to the elimination diet every dog received — so clinical improvement in both arms is the expected diet effect, and the record's abstract reports no between-group clinical-score comparison and no group sizes by arm (one probiotic strain was detected in five of eight probiotic-group dogs after supplementation). The abstract gives a P value for the overall CIBDAI fall but no absolute scores by group, so this card carries the qualitative 'improved in all, no probiotic-specific advantage reported' claim only. Randomisation is not stated in the abstract, so this record does not contribute to the shelf's design class, which rests on White 2017.
Sauter SN, Benyacoub J, Allenspach K, Gaschen F, Ontsouka E, Reuteler G, Cavadini C, Knorr R, Blum JW. Effects of probiotic bacteria in dogs with food responsive diarrhoea treated with an elimination diet. J Anim Physiol Anim Nutr. 2006;90(7-8):269-77. PMID: 16867072. Registry ID: none in the record. MeSH: Animal Feed · Animal Nutritional Physiological Phenomena · Animals · Bifidobacterium/growth & development · Colon/immunology, microbiology*, pathology · Cytokines/biosynthesis* · Diarrhea/drug therapy, microbiology, pathology, veterinary* · Dietary Supplements · Dog Diseases/drug therapy*, microbiology, pathology · Dogs · Double-Blind Method · Duodenum/immunology, microbiology*, pathology · Enterobacteriaceae/growth & development · Enterococcus/growth & development · Feces/microbiology · Female · Food Hypersensitivity/drug therapy, microbiology, pathology, veterinary · Lactobacillus/growth & development · Male · Probiotics* · Prospective Studies · RNA, Messenger/metabolism · Severity of Illness Index · Treatment Outcome
Schmitz 2015: a blinded, placebo-controlled pilot of a single-strain Enterococcus faecium synbiotic found no difference in clinical efficacy — 7 synbiotic vs 5 placebo dogs finished of 45 recruited
Prospective, randomized, blinded, placebo-controlled pilot study (record's own title wording)
Who: Dogs: 45 client-owned dogs diagnosed with food-responsive chronic enteropathy prospectively recruited to receive a hydrolysed elimination diet plus either a synbiotic product containing Enterococcus faecium NCIMB 10415 (with fructo-oligosaccharides) or placebo for 6 weeks; veterinary staff and owners were blinded to treatment. Only 12 dogs finished the trial (7 synbiotic, 5 placebo). Clinical severity (canine chronic enteropathy clinical activity index, CCECAI), clinicopathological data, histology and intestinal gene expression were assessed before and after treatment.
Result: There was no difference between groups or treatments regarding clinical efficacy, histology scores or expression of any of the investigated genes. Standard dietary treatment induced rapid clinical response in all cases. Because the study was underpowered (12 of 45 recruited dogs finished), the authors concluded it was not possible to determine whether or not Enterococcus faecium had an additional effect within the 6-week period.
Watch out: This is a SINGLE-strain synbiotic (Enterococcus faecium plus a prebiotic), not a multi-strain probiotic — it is carded as the second blinded placebo-controlled record in canine chronic enteropathy and bounds any class claim, but the multi-strain claim itself rests on White 2017. Attrition was severe (12 finishers of 45 recruited), the population is food-responsive enteropathy on an elimination diet, and follow-up ended on treatment at 6 weeks, so relapse is again unmeasured.
Schmitz S, Glanemann B, Garden OA, Brooks H, Chang YM, Werling D, Allenspach K. A prospective, randomized, blinded, placebo-controlled pilot study on the effect of Enterococcus faecium on clinical activity and intestinal gene expression in canine food-responsive chronic enteropathy. J Vet Intern Med. 2015;29(2):533-43. PMID: 25776251. Registry ID: none in the record. MeSH: Animals · Dog Diseases/therapy* · Dogs · Enterococcus faecium* · Female · Gene Expression Regulation · Intestinal Diseases/microbiology, therapy, veterinary* · Male · Pilot Projects · Probiotics*
Synthesis: on top of standard therapy, probiotic and placebo remission rates are nearly identical in the blinded trials; relapse after stopping has never been measured — POSSIBLE (the treatment made no difference to clinical remission)
Synthesis
Who: Synthesis of the three carded records above (White 2017, randomised blinded placebo-controlled multi-strain trial, 26 completers; Sauter 2006, placebo-controlled cocktail trial in 21 food-responsive dogs; Schmitz 2015, randomised blinded placebo-controlled single-strain pilot, 12 finishers) and of the near-miss records documented in the result, fetched at drafting and deliberately not carded as claim-carriers for this comparison.
Result: (1) Clinical scores: White 2017 (PMID: 28678609) — remission 12/14 (86%) probiotic vs 10/12 (83%) placebo at ~3 weeks and 13/14 vs 11/12 at 8 weeks, CIBDAI falling in both arms; Sauter 2006 (PMID: 16867072) — CIBDAI fell in all dogs (P < 0.0001) with no probiotic-specific advantage reported; Schmitz 2015 (PMID: 25776251) — no difference in clinical efficacy. In every placebo-controlled record, the improvement tracks the diet (and in White 2017 the prednisone) that all dogs received. (2) Relapse: no carded or near-miss record followed dogs after probiotic treatment stopped, so the 'reduce relapse' half of the mined question has no evidence either way — it is untested, not disproven. (3) Near-miss, not carded: Rossi 2014 (PMID: 24722235) randomised 20 IBD dogs to the multi-strain VSL#3 formulation vs combination prednisone-plus-metronidazole (open label, no placebo); CIBDAI and duodenal histology scores decreased post-treatment in both groups (P < 0.001) — it compares probiotic with drug therapy, not with placebo, so it cannot carry this shelf's comparison. (4) Near-miss, uncardable for a rates claim: D'Angelo 2018 (PMID: 29212912), a prospective non-randomised double-blinded placebo-controlled study of Saccharomyces boulardii (a single yeast, not a multi-strain bacterial probiotic) in 20 dogs with chronic enteropathies, reports that clinical activity index, stool frequency, stool consistency and body condition score 'improved significantly' vs placebo, but its abstract reports no absolute rates or scores by group, so under the rates rule it cannot carry a clinical-benefit claim here; it is noted qualitatively only. (5) A synbiotic-plus-immunoglobulin supplement trial (Sahoo 2023, PMID: 36669027) is a different intervention (synbiotic-IgY) and is not imported. Design class (a) rests on White 2017 alone: randomised, blinded, placebo-controlled, answering this shelf's own add-on comparison in IBD dogs.
Watch out: One-home check at drafting: none of PMIDs 28678609, 16867072, 25776251, 24722235 or 29212912 appears in any other pack on disk. Do not read this shelf as 'probiotics are useless in enteropathy': the trials were small, White 2017 was under its own power target, all tested add-on use over 6–8 weeks, and mechanistic signals (mucosal Lactobacillus, tight-junction proteins) were real but did not translate into clinical scores. Do not import faecal microbiota transplantation evidence (shelves #389/#390) or cobalamin evidence (#393) — different interventions with their own homes.
Synthesis of White R et al. PMID: 28678609; Sauter SN et al. PMID: 16867072; Schmitz S et al. PMID: 25776251; Rossi G et al. PMID: 24722235; D'Angelo S et al. PMID: 29212912; Sahoo DK et al. PMID: 36669027. Registry IDs as on the individual cards (none in the records).
Back to the library index · VetMed home
VetMed is an educational resource, not veterinary advice.